Inpharma 1393 - 28 Jun 2003

■ SLI 381 appears suitable for once-daily dosing inpaediatric patients with attention-deficit hyperactivitydisorder, according to US-based researchers. In thiscrossover study, 51 such patients aged 6–12 yearsreceived an initial dose of oral SLI 381 [‘Adderall-XR’]20mg to assess individual tolerability to the drug.Thereafter, the patients received adderall 10mg, SLI381 at doses of 10mg, 20mg and 30mg, and placebo,once daily for one week each. A total of 48 patientswere eligible for analysis. At study end,pharmacokinetic analyses showed that the mean Tmax

for dextroamphetamine was significantly increased byan average of 3 hours following the administration ofSLI 381 10mg, compared with adderall 10mg.Similarly, the mean Tmax for levoamphetamine wassignificantly increased by 3.2 hours when patientsreceived SLI 381 10mg, compared with adderall 10mg.Substantial interpatient variability in pharmacokineticparameters was observed.McGough JJ, et al. Pharmacokinetics of SLI381 (ADDERALL XR), anextended-release formulation of Adderall. Journal of the American Academyof Child and Adolescent Psychiatry 42: 684-691, Jun 2003 800934305

1

Inpharma 28 Jun 2003 No. 13931173-8324/10/1393-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved